Monica Gray

Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Cellectar (NASDAQ: CLRB) Jumps 35% on Expansion of Phase 2 Trial

Cellectar Biosciences (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that the company will increase the targeted patient enrollment in the relapsed/refractory (R/R) multiple myeloma (MM) cohort of its currently enrolling Phase 2 clinical trial of CLR 131. Data from the MM cohort of the study demonstrated that the treatment exceeded pre-specified criteria for clinically meaningful benefit. As a result, the cohort will be expanded up to as many as 40 patients.

About the Phase 2 Study of CLR 131
The Phase 2 study is being conducted in approximately 10 leading cancer centers in the United States for patients with relapsed or refractory B-cell hematologic cancers.

About CLR 131
Cellectar (CLRB) developed CLR 131 as an investigational compound under development for a range of orphan designated cancers. It is currently being evaluated as a single-dose treatment in a Phase I clinical trial in patients with R/R MM as well as in a Phase II clinical trial for R/R MM and select R/R lymphomas with either a one- or two-dose treatment. Based upon preclinical and interim Phase I study data, treatment with CLR 131 provides a novel approach to treating solid and hematological tumors and may provide patients with therapeutic benefits, including overall survival, an improvement in progression-free survival, surrogate efficacy marker response rate, and overall quality of life.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLRB and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cytori Therapeutics Inc. (NASDAQ:CYTX)

Cytori Therapeutics Inc. (NASDAQ:CYTX) Posts Positive Study Results

Cytori Therapeutics Inc. (NASDAQ:CYTX)

Cytori Therapeutics Inc. (NASDAQ:CYTX) fell 9.1% in after-hours trading following an announcement concerning a reduction in Fibrosis parameters in a scar study using its cell therapy. The study was performed as a preclinical proof of concept in partnership with the Biomedical Advanced Research and Development Authority.

Cytori Therapeutics Inc. (NASDAQ:CYTX)

Scar Study Results

During the pre-clinical trials Adipose-Derived Regenerative Cells, an active component of Cytori Therapeutics Inc. (NASDAQ:CYTX), was injected into deep partial thickness wounds in a porcine model. Six months after injection, wounds treated with ADRCs showed a significant reduction in parameters associated with hypertrophic scarring.

Some of the parameters improved by Cytori Therapeutics Inc. (NASDAQ:CYTX) cell therapy include skin hardness, organization, vascularity and discoloration. Impressed by the results, the therapeutics company plans to carry out a RELIEF trial to assess the therapy in human patients with substantial thermal burn injury. The trial will also evaluate several scar-related parameters.

Treatment of thermal burns is a critical unmet medical need as patients often suffer from pain, scarring and skin contracture on using standard care.

Fibrosis is a common factor in both burns and scleroderma.” said Dr. John Fraser, Chief Scientist at Cytori Therapeutics Inc. (NASDAQ:CYTX). “This preclinical study is consistent with a number of emerging studies indicating a beneficial effect of Cytori ADRC technology in fibrotic disease.”

CYTX Stock Performance

Cytori Therapeutics Inc. (NASDAQ:CYTX) is currently trading in a downtrend, after reporting a third-quarter net loss that appears to have spooked investors. The therapeutics company focused on regenerative and oncologic therapies has underperformed the overall industry this year. The stock is down by more than 70% as it continues to trade near its 52-week low of $0.28 a share.

Investor confidence in the stock has taken a hit on the company reporting revenues of $1.8 million for the third quarter, down from $2.6 million reported last year. Revenue for the first nine months of the year also dropped to $4.9 million from $8.4 million as of last year.

Net loss for the three months ended September 30, 2017, dropped to (-$4.8) million or (-$0.14) a share, compared to (-$5.4) million or (-$0.26) a share reported last year. Cash burn in the quarter stood at $4 million compared to $4.6 million. Cytori Therapeutics Inc. (NASDAQ:CYTX) expects the cash burn for the full year to be slightly lower at between $17 million and $19 million compared to $20 and $23 million as of last year.

Cytori Therapeutics Inc. (NASDAQ:CYTX) plans to pursue a meeting with the U.S. Food and Drug Administration to determine the next step required for regulatory approval of Habeo Cell Therapy for scleroderma-associated hand dysfunction. The company also plans to begin patient enrollment for RELIEF burn clinical trial.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CYTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Heat Biologics Inc. (NASDAQ:HTBX)

This Is Why Heat Biologics Inc. (NASDAQ:HTBX) Dropped 16%

This Is Why Heat Biologics Inc. (NASDAQ:HTBX)

Shares of Heat Biologics Inc. (NASDAQ:HTBX) fell 16.9% after the biopharmaceutical company priced 5.8 million shares, for a common stock offering. The company has priced the offering at $0.43 a share, slightly below the stock’s current price.

Heat Biologics Inc. (NASDAQ:HTBX)

In addition, the company has granted underwriters a 45-day option for the purchase of up to 872,093 shares of common stock at the public offering price. The company expects gross proceeds of approximately $2.5 million before deduction of underwriting discounts and commissions. The offering should close on or about November 21, 2017.

Heat Biologics Inc. (NASDAQ:HTBX) plans to use the net proceeds from the offering to fund its subsidiaries’ pre-clinical and clinical programs and for working capital and general corporate purposes.

HTBX Investor Reaction

News of the public offering did not go well with current investors as it will dilute their current holdings even though the company tries to use it to shore up its balance sheet. Investors’ confidence in the stock is dropping and threatens to push Heat Biologics Inc. (NASDAQ:HTBX) to its 52-week low of $0.41 a share. Heat Biologics has underperformed the overall industry and is currently down by more than 40% for the year

Despite the underperformance, Griffin analyst Keith Markey remains bullish about the stock’s long-term prospects. The analyst has a ‘buy’ rating on the stock with a share price target of $2.25. The price target represents an upside potential of more than 270%.

“Heat Biologics has developed a T cell activation platform (TCAP) to initiate or enhance an immune attack against solid tumors. [..]As such, we view the Company’s immunotherapies to be far more sophisticated than “vaccines” that also use an antigen-based approach to stimulate the immune system,” said Mr., Markey.

Heat Biologics Q3 Financials

Separately, Heat Biologics Inc. (NASDAQ:HTBX) reported a wider than expected net loss of (-$2.3) million or $0.06 a share, compared to a net loss of (-$1.6) million reported last year. Research and development expense increased 8% to $1.8 million primarily due to Chemistry Manufacturing and Control activities.

During the quarter, the company signed a manufacturing agreement with KBI Pharma that will advance the development of its cancer targeting immunotherapies.

“We had a very productive third quarter, as we achieved a number of important milestones,” said Jeff Wolf, CEO of Heat. “We signed a critical manufacturing agreement to further advance our co-stimulatory programs, and we were also granted a Type C meeting with the FDA to review our Phase 2 clinical trial using our HS-110 for the treatment for non-small cell lung cancer

Heat Biologics Inc. (NASDAQ:HTBX) exited the quarter with cash and cash equivalent of approximately $4.3 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $HTBX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Arca Biopharma Inc. (NASDAQ:ABIO)

Arca Biopharma Inc. (NASDAQ:ABIO) Awarded European Patent

Arca Biopharma Inc. (NASDAQ:ABIO)

Arca Biopharma Inc. (NASDAQ:ABIO) traded higher after the European Patent Office granted it a patent on methods for treating cardiovascular disease with a thiol-substituted isosorbide mononitrate. Shares of the company gained 20.83% to end Thursday’s trading session at $1.45 a share.

Arca Biopharma Inc. (NASDAQ:ABIO)

ABIO Stock Performance

Thursday’s rally capped yet another impressive run as the stock continues to bounce back from yearly lows. Arca Biopharma Inc. (NASDAQ:ABIO) has shed more than 40% in market value since the start of the year as short sellers continue to apply pressure. The stock is currently trading in a downtrend and faces immediate resistance at $1.60.

The new European Patent appears to have revitalized investors’ confidence in the stock. Titled Methods of and Compositions for Cardiovascular Disease and Conditions, the patent provides protection for Arca Biopharma Inc. (NASDAQ:ABIO) approach for treating patients with cardiovascular diseases and conditions.

AB171 Development

The biopharmaceutical company has discovered what it believes is a pharmacogenetic target for AB171, which can be used in genetically targeted cardiovascular development programs. ARCA plans to advance the development of AB171 for the treatment of peripheral arterial disease and for chronic heart failure.

“The addition of AB171 to our genetically-targeted development pipeline, including the Gencaro atrial fibrillation-heart failure program, is consistent with that mission. We believe our experience with GENETIC-AF has established the feasibility of in-house design and execution of pharmacogenetic clinical trials, and has provided invaluable insights into this type of drug development,” said CEO, Michael Bristow.

Arca Biopharma Inc. (NASDAQ:ABIO) expects top-line results on a Phase 2B Genetic-AF trial in the latter part of the first quarter of 2018. The Phase 2B trial will be investigating the safety and efficacy of Gencaro to Toprol-XL for the treatment and prevention of atrial fibrillation or heart flutter.

“We are focused on executing our genetically-targeted approach to cardiovascular drug development and look forward to furthering our development of Gencaro as well as initiating additional pharmacogenetic development programs..,” said Mr. Brostow.

Arca Q3 Financial Results

Separately, Arca Biopharma Inc. (NASDAQ:ABIO) reported a net loss of (-$4.4) million or (-$0.39) a share, for the three months ended September 30, 2017. Net loss for the first nine months of the year came in at (-$14.3) million compared to a net loss of (-$12.2) million for the corresponding period last year. Research and development expenses for the quarter totaled $3.5 million compared to $3.7 million for Q3 2016.

Arca Biopharma Inc. (NASDAQ:ABIO) exited the quarter with cash and cash equivalent of $16 million compared to $23.5 million as of December 31, 2016. The cash balance is sufficient to fund operations and projected cost structure through the end of the second quarter of 2018.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ABIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Egalet Corp (NASDAQ:EGLT)

Egalet Corp (NASDAQ:EGLT) Moves on Topline Trial Results

Egalet Corp (NASDAQ:EGLT)

Egalet Corp (NASDAQ:EGLT) was a big mover after announcing top-line trial results from a phase 3 safety study of its abuse-deterrent oxycodone formulation Egalet-002. Shares of the company gained 38.55% after it emerged the formulation was well tolerated, and adverse events reported were consistent with expected outcomes.

Egalet Corp (NASDAQ:EGLT)

Egalet-002 Top Line Results

According to the Chief Executive Officer, Bob Radie, the positive Phase 3 safety study results validates the company’s Guardian technology, which is being used to develop abuse-deterrent formulations of prescription medications.

Last year, Egalet Corp (NASDAQ:EGLT) reported positive top-line result from a category 3 intranasal human abuse potential study of Egalet. The formulation is currently in late-stage development for the management of pain severe enough to require daily, long-term opioid treatment for which other treatment options are inadequate.

Despite the 38% rally, Egalet Corp (NASDAQ:EGLT) continues to trade in a downtrend after underperforming the overall industry for the better part of the year. The stock has shed more than 80% in market value since the start of the year and is currently trading near all-time lows. Shares of the company closed at $1.15, last year they were trading at $5.58 a share.

Despite the underperformance, the Chief Executive Officer remains bullish about the company’s long-term prospects as they move to address the prescription abuse crisis.

“With 124% prescription growth and 41% revenue growth for our marketed products over last year’s third quarter, we continue to grow our business With a cash position of $102.1 million and the increased focus on non-narcotic and innovative treatments to alleviate pain,” said Mr. Radie

For the three months ended September 30, 2017, Egalet Corp (NASDAQ:EGLT) registered a 101% increase in Nasal Spray prescriptions over the third quarter of 2016. The company also partnered Ascend Therapeutics to begin promotion of SPRIX Nasal Spray to over 11,000 target women healthcare providers.

Egalet Q3 Financial Results

Net product sales for the third quarter came in at $6.7 million compared to $4.7 million reported last year. Cost of sales was $1.2 million up from $914,000 as of last year and reflected the average cost of inventory produced and dispensed to patients. General and Administrative expenses dropped to $6.8 million from $8 million as of the corresponding period last.

Egalet Corp (NASDAQ:EGLT) generated a net loss of (-$18.9) million in Q3 2017 or (-$0.46) a share, compared to a net loss of (-$26.9) million or (-$1.10) reported last year. The earnings exceeded Wall Street expectations as analysts were expecting a net loss of (-$0.47) cents a share. The integrated specialty pharmaceutical company exited the quarter with cash and cash equivalent of $102.1 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EGLT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

CASI Pharmaceuticals Inc. (NASDAQ:CASI) Reports Narrow Q3 Net Loss

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) gained 8.37% after the biopharmaceutical company reported a narrower than expected net loss for the three and nine months ended September 30, 2017. In addition, the company was able to strengthen its balance sheet through the issuance of shares to certain investors.

CASI Pharmaceuticals Inc. (NASDAQ:CASI)

Declining Net Loss

Net loss for the third quarter came in at ($1.6) million or (-$0.03) a share, compared to a net loss of (-$1.7) million reported last year. For the first nine months of the year, CASI Pharmaceuticals net loss totaled (-$5.7) million, compared to a net loss of (-$6.8) million reported last year.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) attributes the decline in net loss to a decrease in non-cash compensation expense associated with stock option issuance. Clinical expenses associated with the development of the company’s lead candidate drug ENMD-2076 were also down in the quarter.

“I am pleased with our third quarter financial results. In October, we announced a $23.8 million registered direct offering, funds raised from which will be used to advance our internal pipeline and support our business development in-license activities,” said CEO Ken K. Ren.

CASI Stock Performance

Investors reacted to the declining net loss by pushing the stock up the chart. The stock is currently trading in an uptrend as it makes a push for its 52-week high of $3.18 a share. CASI Pharmaceuticals is up by more than 100% for the year, as it continues to outperform the overall industry.

Data compiled by Zacks Investment Research indicates that the stock is currently rated as a ‘strong buy’ by one analyst firm. Analysts are forecasting a 14.71% year over year increase in earnings this year compared to last year. However, the analysts expect a -6.9% earnings growth next year.

Public Offering

Separately, China’s Food and Drug Administration has granted a priority review for CASI Pharmaceuticals Inc. (NASDAQ:CASI) clinical trial application for EVOMELA for injection. Depending on the review, the company could make a clinical trial application by the end of the year.

In September, CASI Pharmaceuticals Inc. (NASDAQ:CASI) entered into agreements with certain institutional and accredited investors for the purchase of approximately $23.8 million securities in a direct offering. The company expects net proceeds of $23.3 million that is to be used to support business development activities which includes advancing clinical trial programs.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CASI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) Q3 Earnings Disappoint

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) fell 4.4% as investors reacted to the company’s third quarter financial results and corporate update. The clinical stage pharmaceutical company did not report any revenue for the three months ended September 30, 2017, as it is in the research and development phase.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa’s Pipeline Development

Operating expenses for the quarter totaled $2.1 million and $5.6 million for the first nine months of the year. Research and development expenses in the quarter increased to $0.7 million from $0.1 million reported last year.

During the quarter, Atossa Genetics Inc. (NASDAQ:ATOS) announced preliminary results from a Phase 1 study of its lead candidate drug Endoxifen. The drug met its primary endpoint with no significant safety signal or adverse events.

Atossa Genetics is currently preparing for a Phase 2 study that will evaluate Endoxifen for the treatment of women with mammographic breast density. The study will be conducted in partnership with the Stockholm South General Hospital in Sweden.

“We are very pleased with our recent clinical progress with our Endoxifen programs. Preliminary results from our Phase 1 study show that all objectives of both our proprietary topical and oral formulations of Endoxifen have been met. We recently raised capital to support advancement of our Endoxifen,” said CEO, Steve Quay

Atossa Genetics Inc. (NASDAQ:ATOS) underperformance continued in the market following the third quarter financial results. The stock is currently languishing as it closes in on its 52-week low of $0.32 a share. The stock has shed more than 70% in market value since the start of the year. As it stands, the stock needs a new catalyst if it is to bounce back.

ATOS Public Offering Impact

Declining investor confidence in Atossa Genetics follows the pricing of a public offering of the company’s common shares at a deep discount. The move did not go well with investors. The public offering’s pricing triggered a selloff of the stock to current lows.

Atossa Genetics issued 11.5 million shares of common stock priced at $0.44 a share. The company also offered underwriters the option of purchasing an additional 1 million shares pursuant to the over-allotment option.

Gross proceeds before deduction of underwriting discounts commissions and the offering costs were approximately $5.5 million. Atossa Genetics Inc. (NASDAQ:ATOS) plans to use net proceeds from the offering for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Celsion Corporation (NASDAQ:CLSN) Q3 Results Disappoint

Celsion Corporation (NASDAQ:CLSN)

Shares of Celsion Corporation (NASDAQ:CLSN) fell 5.2% after the oncology drug development company reported financial results for the three and nine months ended September 30, 2017. A net loss for the two periods appears to have spooked the market, fuelling a sell-off of the stock.

Celsion Corporation (NASDAQ:CLSN)

CLSN Sell-Off

Following Tuesday’s sell-off, Celsion Corporation (NASDAQ:CLSN) is at risk of dropping to this year’s lows as it continues to trade in a strong downtrend. The stock has shed more than 50% in market value since the start of the year as investors continue to question the company’s long-term prospects.

However, data compiled by Zacks Investment Research indicates that two analyst firms currently rate the stock as a ‘strong buy’ amidst the growing short interest. Despite disappointing financial results, analysts are forecasting a 76.6% year over year increase in earnings. The analysts also expect earnings to grow by 48.4% next year.

For the quarter ended September 30, 2017, Celsion Corporation (NASDAQ:CLSN) reported a net loss of (-$5.7) million or (-$0.70) a share compared to a net loss of (-$6.4) million reported last year. The company attributes the decrease to a tighter clinical development focus coupled with lower operational expenses. Net loss for the first nine months came in at (-$16.1) million compared to (-$16.7) million as of last year.

Celsion Pipeline Development

During the quarter Celsion Corporation (NASDAQ:CLSN) recognized deemed dividends totaling $0.4 million with regards to multiple agreements with certain warrant holders. The company also made important milestones in the development of its lead clinical programs and capital infusion of $38 million to help drive the development efforts.

Celsion Corporation (NASDAQ:CLSN) is currently working on ThermoDox, its proprietary heat-activated liposomal encapsulation currently in Phase III for the treatment of primary liver cancer. The company’s immunotherapy program consisting of GEN-1 is currently in Phase 1 development as a localized treatment for Ovarian Cancer.

“We believe that we now have sufficient capital to complete enrollment of our Phase III OPTIMA Study and through the first efficacy analysis expected in the first quarter of 2019. Further, we expect that our current funds will allow us to make substantial progress in our open-label, randomized, 86 patient Phase I/II study of GEN-1 in newly diagnosed stage III and IV ovarian cancer patients,” said CEO, Michael Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Asure Software Inc. (NASDAQ:ASUR) Spikes After Record Q3

Asure Software Inc. (NASDAQ:ASUR)

Asure Software Inc. (NASDAQ:ASUR) shares gained 12.97% after the Austin-based maker of human capital management programs reported record revenue for the third quarter. The achievement was driven by continued growth across the entire business as the company continued to integrate multiple acquisitions made this year.

Asure Software Inc. (NASDAQ:ASUR)

ASUR Stock Performance

The better-than-expected third quarter financial results helped strengthen the stock’s sentiments on Wall Street. Investors’ confidence appears to be slowly building up, the stock having come under pressure in recent months.

For the full year, Asure Software Inc. (NASDAQ:ASUR) is up by more than 40%. The stock faces immediate resistance at the $13.50 mark, above which it could make a push for its 52-week high of $16.03 a share.

Asure’s Q3 Financial Results

Revenue for the three months ended September 30, 2017, increased 65% to $15.5 million. Cloud revenue was up 97%, as hardware revenue increased 48% compared to the third quarter of 2016. Gross margin came in at $12.1 million or 78.1% of total revenue, representing a 64% increase from $7.4 million reported last year.

Asure Software Inc. (NASDAQ:ASUR) reported a net income per share of $0.15 a share compared to a non-GAAP net income per share of $0.22 a share reported last year. The Chief Financial Officer, Kelyn Brannon, attributes the better than expected Q3 financial results to the execution of a cloud sales initiative that helped produce solid gross margins and recurring revenue.

“Additionally, our strong cash position as well as our investments in infrastructure and processes has increased the operating leverage of our business model. Overall, our results in the third quarter reflect the increasing demand for our solutions as well as the cost and operational synergies from the strategic acquisitions we have completed this year,” said Mr. Brannon.

For the full year, Asure Software Inc. (NASDAQ:ASUR) expects revenue of between $54.25 million and $56.25 million. Excluding one-time items, Non-GAAP EBITDA should range between $12.2 million and $13.5 million. The company is also projecting Non-GAAP net loss per share of between $0.06 and $0.02 a share.

Asure Software is projecting revenues of $70 million for 2018 as it moves to integrate already completed acquisitions. The company also plans to carry out multiple ‘tuck-in” acquisitions of service bureaus, which could drive further growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ASUR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Drops As Earnings Beat

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) fell 13.93% after the company reported on its Phase 1 clinical data for IPI-549, an oral selective phosphoinositide-3-kinase-gamma targeting immune-suppressive tumor macrophages. Trial results indicate that the candidate drug was well tolerated and clinically active.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Clinical Trial Results

The sell-off on Infinity Pharmaceuticals Inc. (NASDAQ:INFI) stock comes as a surprise, given that the biopharmaceutical company is fresh from posting a narrower than expected third-quarter net loss. However, the stock is still trading in an uptrend despite coming under pressure in recent trading sessions. The stock is up by more than 60% for the year, as it continues to outperform the overall industry.

The positive IPI-549 and Q3 financial results should affect the stock’s direction of trade heading into the end of the year.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is evaluating IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced tumors.

There is a significant need for better treatment options to take care of patients who do not respond to existing immunotherapies.

“In particular, patients with mesothelioma and adrenocortical carcinoma have limited effective treatment options, and our early evidence of activity suggests the potential for IPI-549 to improve outcomes for these patients,” said CEO Adeline Perkins.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is to report data from a monotherapy expansion component of the study in the first half of 2018. The company also plans to report data from a combination expansion component in the first half of next year.

Infinity Q3 Financial Results

For the three months ended September 30, 2017, Infinity Pharmaceuticals posted a net loss of (-$7.1) million or (-$0.14) million, compared to a net loss of (-$19.5) million reported last year. Revenue in the quarter totaled $6 million related to amounts due from Verastem for the DUO study.

Restructuring activities in the quarter resulted in research and development expenses dropping to $9.3 million, from $12.8 million reported last year. Infinity Pharmaceuticals exited the quarter with cash and cash equivalent of $55.6 million compared to $66.2 million as of June 30, 2016. General and Administrative expenses also dropped because of the restructuring activities to $4.5 million from $7.1 million a year ago.

For the full year, the biopharmaceutical company is projecting a net loss of between $40 million and $50 million. Cash and cash equivalents should range from $40 million and $50 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $INFI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.